Overview

Re-treatment 225Ac-J591 for mCRPC

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if re-treatment with 225Ac-J591 can be given without severe side effects.
Phase:
Early Phase 1
Details
Lead Sponsor:
Weill Medical College of Cornell University
Treatments:
Gallium 68 PSMA-11